Clara Hwang1, Elisabeth I Heath. Show Affiliations » 1. Henry Ford Health Systems, Detroit, MI.
Abstract
Entities: Disease
Mesh： See more » Angiogenesis Inhibitors/therapeutic useBiopsyCarcinoma, Renal Cell/blood supplyCarcinoma, Renal Cell/enzymologyCarcinoma, Renal Cell/secondaryCarcinoma, Renal Cell/therapyDisease ProgressionFatal OutcomeHumansKidney Neoplasms/blood supplyKidney Neoplasms/enzymologyKidney Neoplasms/pathologyKidney Neoplasms/therapyLiver Neoplasms/secondaryLung Neoplasms/blood supplyLung Neoplasms/drug therapyLung Neoplasms/enzymologyLung Neoplasms/secondaryMaleMiddle AgedMolecular Targeted TherapyNeoplasm GradingNeoplasm StagingNephrectomyPatient SelectionPrecision MedicineProtein Kinase Inhibitors/therapeutic useReceptors, Vascular Endothelial Growth Factor/antagonists & inhibitorsReceptors, Vascular Endothelial Growth Factor/metabolismTOR Serine-Threonine Kinases/antagonists & inhibitorsTOR Serine-Threonine Kinases/metabolismTime FactorsTomography, X-Ray ComputedTreatment OutcomeTumor Burden
Substances： See more » Angiogenesis InhibitorsProtein Kinase InhibitorsMTOR protein, humanTOR Serine-Threonine KinasesReceptors, Vascular Endothelial Growth Factor
Year: 2014 PMID： 24516012 DOI： 10.1200/JCO.2013.53.6029
Source DB: PubMed Journal: J Clin Oncol ISSN： 0732-183X Impact factor: 44.544